• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
74,243.34 -116.67
( -0.16%)
Global Indices
Nasdaq
51,098.17 -484.76
(-0.94%)
Dow Jones
7,440.28 -165.03
(-2.17%)
Hang Seng
66,711.59 -759.10
(-1.13%)
Nikkei 225
10,374.30 13.98
(0.13%)
Forex
USD-INR
95.73 0.01
(0.01%)
EUR-INR
111.21 0.07
(0.06%)
GBP-INR
128.58 -0.06
(-0.05%)
JPY-INR
0.60 0.00
(0.01%)

EQUITY - MARKET SCREENER

Valiant Laboratories Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
543998
INE0JWS01017
58.8745685
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
VALIANTLAB
72.38
400.99
EPS(TTM)
Face Value()
Div & Yield %
1.02
10
0
 

deccan gold mines ltd
Nelco slumps on reporting dismal Q3 performance
Jan 16,2026

Total income declined 4.08% YoY to Rs 78.88 crore in Q3 FY26, from Rs 82.24 crore in the corresponding quarter last year.

The company reported a loss before tax of Rs 1.73 crore in Q3 FY26, against a profit before tax of Rs 6.98 crore in Q3 FY25.

Total expenses rose 2.83% YoY to Rs 70.48 crore, compared with Rs 68.54 crore in Q3 FY25. Purchase of stock-in-trade stood at Rs 14.72 crore, up 99.59% YoY during the quarter.

On a standalone basis, the company’s net profit declined 0.57% YoY to Rs 0.87 crore in Q3 FY26, compared with Rs 0.88 crore in Q3 FY25. Total income fell 4.52% YoY to Rs 50.23 crore during the quarter.

Nelco provides domestic satellite communication services to closed user group networks.